EGFR-mutated NSCLC: practice-changing results and other notable findings

被引：0
|
作者：
不详
机构：
来源：
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY | 2023年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S188 / S192
页数：5
相关论文
共 50 条
  • [31] Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy
    Aredo, Jacqueline V.
    Mambetsariev, Isa
    Hellyer, Jessica A.
    Amini, Arya
    Neal, Joel W.
    Padda, Sukhmani K.
    McCoach, Caroline E.
    Riess, Jonathan W.
    Cabebe, Elwyn C.
    Naidoo, Jarushka
    Abuali, Tariq
    Salgia, Ravi
    Loo Jr, Billy W.
    Diehn, Maximilian
    Han, Summer S.
    Wakelee, Heather A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (06) : 1030 - 1041
  • [32] Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
    Tsuboi, Masahiro
    Herbst, Roy S.
    John, Thomas
    Kato, Terufumi
    Majem, Margarita
    Grohe, Christian
    Wang, Jie
    Goldman, Jonathan W.
    Lu, Shun
    de Marinis, Filippo
    Shepherd, Frances A.
    Lee, Ki Hyeong
    Le, Nhieu Thi
    Dechaphunkul, Arunee
    Kowalski, Dariusz
    Bonanno, Laura
    Domine, Manuel
    Poole, Lynne
    Bolanos, Ana
    Rukazenkov, Yuri
    Wu, Yi-Long
    TARGETED ONCOLOGY, 2024, 19 (02) : 131 - 134
  • [33] Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC
    Rosenfeld, Roberto
    NEW ENGLAND JOURNAL OF MEDICINE, 2025, 392 (06): : 619 - 620
  • [34] Predictors of Health Utility Scores (HUS) in Advanced EGFR-Mutated NSCLC
    Jiang, S.
    Hurry, M.
    Hueniken, K.
    Brown, M. C.
    Liang, M.
    Patel, D.
    Labbe, C.
    Eng, L.
    Naik, H.
    Bradbury, P.
    Leighl, N.
    Shepherd, F.
    Xu, W.
    Liu, G.
    Walton, R.
    O'Kane, G.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S420 - S421
  • [35] Osimertinib in Stage III EGFR-Mutated NSCLC - Game, Set, Match
    Leighl, Natasha B.
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (07): : 652 - 654
  • [36] New Practice-Changing Study Findings Presented at ASCO
    O'Rourke, Kate
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2014, 312 (03): : 218 - 219
  • [37] Practice-Changing Results Presented at Plenary Session
    不详
    AMERICAN JOURNAL OF MANAGED CARE, 2016, 22 : 8 - 16
  • [38] Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC
    Kei Kunimasa
    Kazumi Nishino
    Yoshiharu Sato
    Masahide Mori
    Shoichi Ihara
    Hidekazu Suzuki
    Izumi Nagatomo
    Toru Kumagai
    Toshitaka Morishima
    Fumio Imamura
    Scientific Reports, 12
  • [39] Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC
    Kunimasa, Kei
    Nishino, Kazumi
    Sato, Yoshiharu
    Mori, Masahide
    Ihara, Shoichi
    Suzuki, Hidekazu
    Nagatomo, Izumi
    Kumagai, Toru
    Morishima, Toshitaka
    Imamura, Fumio
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [40] NSCLC presents metabolic heterogeneity, and there is still some leeway for EGF stimuli in EGFR-mutated NSCLC
    Mendes, Cindy
    Lemos, Isabel
    Francisco, Ines
    Almodovar, Teresa
    Cunha, Fernando
    Albuquerque, Cristina
    Goncalves, Luis G.
    Serpa, Jacinta
    LUNG CANCER, 2023, 182
12345